Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Issues Quarterly Earnings Results

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) released its earnings results on Tuesday. The company reported $0.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.06, Zacks reports. Bayer Aktiengesellschaft had a positive return on equity of 17.61% and a negative net margin of 4.75%.

Bayer Aktiengesellschaft Price Performance

BAYRY opened at $13.57 on Tuesday. Bayer Aktiengesellschaft has a 52-week low of $7.19 and a 52-week high of $15.23. The company has a market cap of $53.33 billion, a P/E ratio of -21.20, a P/E/G ratio of 4.46 and a beta of 0.55. The company has a quick ratio of 0.70, a current ratio of 1.05 and a debt-to-equity ratio of 1.06. The company has a 50 day moving average of $12.36 and a two-hundred day moving average of $12.08.

Analyst Ratings Changes

Several analysts have weighed in on BAYRY shares. Deutsche Bank Aktiengesellschaft raised Bayer Aktiengesellschaft from a “hold” rating to a “buy” rating in a report on Thursday, July 2nd. Jefferies Financial Group upgraded shares of Bayer Aktiengesellschaft to a “hold” rating in a research report on Friday, May 29th. Zacks Research raised shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 10th. Finally, DZ Bank upgraded shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 19th. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy”.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.